loader2
Partner With Us NRI

Procter & Gamble Health Ltd share Price Today

Company details

4,666.50
4,749.80
4,575.00
5,642.85
6M Return -8.38%
1Y Return -0.34%
Mkt Cap.(Cr) 7,859.21
Volume 6,047
Div Yield 1.30%
OI
-
OI Chg %
-
Volume 6,047

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Revenue beat but margins miss; focus on power brands continues…
About The Stock

    Procter & Gamble Health is a leading pharma cum OTC company with key focus on the vitamins, minerals, supplement (VMS) category. • It has legacy brands in the VMS category like Neurobion, Polybion, Evion (all vitamins), Livogen (iron supplement), Nasivion (nasal decongestant), Seven Seas (vitamin- substitute for malt based health drinks) • The company was earlier known as Merck Ltd and was part of Merck KGaA, Germany. In 2018 it (as a consumer health business) was acquired by P&G

Q3FY23

    Beat on revenue front but margins were a big miss. • Revenue grew 19.8% YoY to ₹ 321 crore • On the operational front, EBITDA grew 15.8 % YoY to ₹ 79.7 crore whereas margins were at 24.8% • PAT came in at ₹ 59.2 crore

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Procter & Gamble Health announced Q2FY24 results:

  • In a challenging operating environment, the company reported sales of Rs 304 crore, at par vs a year ago.
  • The Profit After Tax (PAT) for the quarter was Rs 72 crore, down 6% vs year ago, owing to one-time items in the quarter.
  • Excluding this one-time impact, Profit After Tax (PAT) was up by 2% vs a year ago.

Milind Thatte, Managing Director, P&G Health India, said, “This has been a challenging quarter for the Company on account of an overall slowdown in the Vitamins, Minerals and Supplements category coupled with a delayed seasonal onset. The team continued to stay resilient. With improved productivity, efficiency and continued strategic investments, we have been able to deliver a modest topline and bottom-line.

We remain committed to our integrated growth strategy of a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure. We are confident that this strategy combined with our operational agility will help us navigate the mid-term and deliver balanced growth.”

 

Result PDF

View Other Company Results

Procter & Gamble Health Ltd shares SWOT Analysis

Strengths (9)

  • Rising Net Cash Flow and Cash from Operating activity
  • Effectively using its capital to generate profit - RoCE improving in last 2 years
  • Growth in Net Profit with increasing Profit Margin (QoQ)

Weakness (2)

  • Near 52 Week Low
  • Weak Momentum: Price below Short, Medium and Long Term Averages

Opportunity (0)

Data not found

Threats (1)

  • RSI indicating price weakness

Resistance and support

R1 4,767.5
R2 4,800.3
R3 4,850.8
Pivot

4,717.02

S1 4,684.2
S2 4,633.7
S3 4,600.9
EMA SMA
4,817.4
4,936.6
5,006.4
4,998.8
4,794.6
5,014.6
5,050.7
5,088.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-03 4106.95 44711 NSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-03 4106.95 6405 NSE
ISHARES CORE EMERGING MARKETS MAURITIUS CO Block Sell 2022-10-03 4106.95 44711 NSE
Name Category Shares
PROCTER AND GAMBLE OVERSEAS INDIA B.V. PROMOTER 51.82%

OUR RESEARCH VIEW

Investment recommendation
Revenue beat but margins miss; focus on power brands continues…
Call Date
16 May 2023
Entry Price 4,735.00
Target Price 5,620.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Procter & Gamble Health Ltd Stocks COMPARISON

Financials( in Cr) Procter & Gamble Health Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Divis Laboratories Ltd
Price 4,734.75 1,537.55 1,375.20 6,050.35 3,764.20
% Change 1.01 -0.16 -0.45 0.66 1.28
Mcap Cr 7,859.21 368,909.75 111,026.77 100,925.28 99,927.84
Revenue TTM Cr 1,229.62 43,885.68 15,790.60 24,669.70 7,767.51
Net Profit TTM Cr 229.47 8,560.84 2,513.47 4,507.30 1,823.38
PE TTM 34.56 39.31 28.09 19.31 72.26
1 Year Return -0.34 53.96 51.71 24.69 19.02
ROCE 43.16 16.79 14.76 25.99 19.30
ROE 33.56 16.46 10.66 21.21 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 750.89 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 27,985.89 -4,210.70
LAST 3M 85,258.15 42,414.35
LAST 6M 136,201.24 75,801.89
LAST 12M 211,048.21 200,392.08
Procter & Gamble Health Limited - Certificate from Debenture Trustee

Apr 15, 2024 l NSE Announcement

Procter & Gamble Health Limited - Loss of Share Certificates

Apr 12, 2024 l NSE Announcement

Procter & Gamble Health Limited - Loss of Share Certificates

Apr 10, 2024 l NSE Announcement

Date Action Type Ratio
Feb 14, 2024 Dividend 500
Feb 14, 2024 Dividend 1500
Nov 23, 2023 Dividend 500

Procter & Gamble Health Ltd Information

Stock PE (TTM)
34.56
Promoter Holding
51.82%
Book Value
485.4699
ROCE
43.16%
ROE
33.56%
Description
  • Proctor & Gamble Health Ltd is in the Pharmaceuticals sector is having a market capitalization worth Rs. 8,936.24 crores, it was incorporated in the year 1967. It has reported consolidated sales of Rs. 22,239.0 crores in March’2021. The company is listed on the Bombay Stock Exchange (BSE) with the code 500126 and is listed on the National Stock Exchange (NSE) with the code PGHL.

    Proctor & Gamble Health Ltd, originally incorporated under the name Merck Ltd, is involved in manufacturing and supplying pharmaceuticals and chemicals. The company's pharmaceuticals division is involved in producing prescription drugs, biotechnology products, and consumer health products. At the same time, the chemicals division is involved in supplying pharmaceutical chemicals, formulated chemical products, industrial chemicals, and other chemical products. Proctor & Gamble completed the acquisition of Merck Ltd in December’2018. Its manufacturing facility is established in Goa. Proctor & Gamble Health Ltd, in pursuing the Corporate Social Responsibility requirements, have introduced various health and education schemes aimed at underprivileged children and women of the country. The promoters of the company own 51.82% of the stake in the company, Foreign Institutional Investors (FII) own 6.45%, Domestic Institutional Investors (DII) own 11.81% stake in the company, and others (such as public & retail investors) hold the balance of 29.92%.

    In March 2021, quarterly net revenue was Rs. 219.15 crores, which has decreased marginally by approximately 3.93 % from Rs. 228.11 crores for the January-March 2020 quarter. The quarterly net profit in March 2021 was Rs. 15.17 crores, which has reduced and decreased by nearly 67.35% from a net profit of Rs. 46.46 crores in March 2020. In March 2021, the reported operating profit was at Rs. 138.29 crores, which is also decreased by 19.76% as compared to an operating profit of Rs. 172.34 crores for the quarter ending in March 2020. From an EPS of Rs. 28 in March 2020, the EPS of Proctor & Gamble Health Ltd has reduced and reached Rs. 9.5 per share in March 2021. PGHL's stock closed at Rs. 5,383.60 on 20th August’2021 (NSE) and has given a negative return of 23.78% in the last six months and an annual return of 14.67% in the previous year.

Registered Address

Godrej One 8th Floor, Projshanagar Vikhroli (East), Mumbai, Maharashtra, 400079

Tel : 91-22-62109000
Email : investorgrievance.im:pg.com
Website : http://www.pghealthindia.com
Registrar

Sharepro Services India P Ltd

AGM Date (Month) : Nov
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 500126
NSE Code : PGHL
Book Closure Date (Month) : Nov
BSE Group : A
ISIN : INE199A01012

FAQ’s on Procter & Gamble Health Ltd Shares

You can buy Procter & Gamble Health Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Procter & Gamble Health Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Apr 16, 2024 03:56 PM the closing price of Procter & Gamble Health Ltd was ₹ 4,734.75.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Apr 16, 2024 03:56 PM, the market cap of Procter & Gamble Health Ltd stood at ₹ 7,859.21.

The latest PE ratio of Procter & Gamble Health Ltd as of Apr 16, 2024 03:56 PM is 34.56

The latest PB ratio of Procter & Gamble Health Ltd as of Apr 16, 2024 03:56 PM is 0.10

The 52-week high of Procter & Gamble Health Ltd share price is ₹ 5,642.85 while the 52-week low is ₹ 4,575.00

According to analyst recommendations, Procter & Gamble Health Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app